<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ESMOLOL HYDROCHLORIDE- esmolol hydrochloride injection, solution </strong><br>Mylan Institutional LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52a10212-3eb1-491c-9585-5df86665a995"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only </span></p>
<p>Ready-to-use Vials</p>
<p>10 mL Vials</p>
<p><span class="Bold">For Intravenous Use </span></p>
<p><span class="Bold">Can be used for direct intravenous use. </span></p>
<p>Esmolol Hydrochloride concentration = 10 milligrams/mL (10,000 micrograms/mL)</p>
<p><span class="Bold">Single Patient Use Only </span></p>
<p><span class="Bold">No Preservatives Added </span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_344a760b-2986-4536-97f0-8c67ff6af55f"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Esmolol hydrochloride is a beta<span class="Sub">1</span>-selective (cardioselective) adrenergic receptor blocking agent with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:</p>
<p>(±)-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnamate hydrochloride and has the following structure:</p>
<p>                              <a name="id251"></a><img alt="Esmolol Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94f069f9-dd52-4a69-a103-ebdb4294f088&amp;name=aaa7c217-e7e3-4e8e-88ea-6ec5c1a8d1b9-01.jpg"></p>
<p>Esmolol hydrochloride has the molecular formula C<span class="Sub">16</span>H<span class="Sub">26</span>NO<span class="Sub">4</span>Cl and a molecular weight of 331.8. It has one asymmetric center and exists as an enantiomeric pair.</p>
<p>Esmolol hydrochloride is a white to off-white crystalline powder. It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9706ff69-ce8c-4900-8a51-31816c95e7d3"></a><a name="section-2.1"></a><p></p>
<h2>Esmolol Hydrochloride Injection, 10 mg/mL</h2>
<p class="First">Esmolol hydrochloride injection, 10 mg/mL is a clear, colorless to light yellow, sterile, nonpyrogenic solution.</p>
<p><span class="Bold">100 mg, 10 mL Single Dose Vial </span>- Each mL contains 10 mg Esmolol Hydrochloride and Water for Injection; buffered with 1.688 mg Sodium Acetate Anhydrous (equivalent to 2.8 mg Sodium Acetate Trihydrate) and 0.546 mg Glacial Acetic Acid. Sodium Hydroxide and/or Hydrochloric Acid added as necessary, to adjust pH to 4.5 to 5.5.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_b3977b26-779b-43cd-b90a-7210e3902536"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Esmolol hydrochloride is a beta<span class="Sub">1</span>-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol inhibits the beta<span class="Sub">1</span> receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta<span class="Sub">2</span> receptors located chiefly in the bronchial and vascular musculature.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_2631c674-8d0b-4dad-812c-442d1a0753db"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism </h2>
<p class="First">Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterases</span> or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes.</p>
<p>Using an appropriate loading dose, steady-state blood levels of esmolol for dosages from 50 to 300 mcg/kg/min (0.05 to 0.3 mg/kg/min) are obtained within five minutes. (Steady-state is reached in about 30 minutes without the loading dose.) Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range. Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion. Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion.</p>
<p>Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine. Within 24 hours of the end of infusion, approximately 73% to 88% of the dosage has been accounted for in the urine as the acid metabolite of esmolol.</p>
<p>Metabolism of esmolol results in the formation of the corresponding free acid and methanol. The acid metabolite has been shown in animals to have about 1/1500th the activity of esmolol and in normal volunteers its blood levels do not correspond to the level of beta blockade. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. Excretion of the acid metabolite is significantly decreased in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, with the elimination half-life increased to about ten-fold that of normals, and plasma levels considerably elevated.</p>
<p>Methanol blood levels, monitored in subjects receiving esmolol for up to 6 hours at 300 mcg/kg/min (0.3 mg/kg/min) and 24 hours at 150 mcg/kg/min (0.15 mg/kg/min), approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity.</p>
<p>Esmolol has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_7023fdd7-4240-4383-9abe-716afd8c7e1f"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacodynamics </h2>
<p class="First">Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of esmolol, showing reduction in heart rate at rest and during exercise, and attenuation of isoproterenol-induced increases in heart rate. Blood levels of esmolol have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10 to 20 minutes.</p>
<p>In human electrophysiology studies, esmolol produced effects typical of a beta blocker; a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade <span class="product-label-link" type="condition" conceptid="318448" conceptname="Second degree atrioventricular block">Wenckebach</span> cycle length.</p>
<p>In patients undergoing radionuclide angiography, esmolol, at dosages of 200 mcg/kg/min (0.2 mg/kg/min), produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg). During exercise, esmolol produced reductions in heart rate, rate pressure product and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> which were also similar to those produced by propranolol, but produced a significantly larger <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in systolic blood pressure. In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min (0.3 mg/kg/min) of esmolol produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At thirty minutes after the discontinuation of esmolol infusion, all of the hemodynamic parameters had returned to pretreatment levels.</p>
<p>The relative cardioselectivity of esmolol was demonstrated in 10 mildly <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients. Infusions of esmolol [100, 200 and 300 mcg/kg/min (0.1, 0.2 and 0.3 mg/kg/min)] produced no significant increases in specific airway resistance compared to placebo. At 300 mcg/kg/min (0.3 mg/kg/min), esmolol produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and esmolol was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. No adverse pulmonary effects were observed in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> who received therapeutic dosages of esmolol for treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (51 patients) or in perioperative settings (32 patients).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f8adcb91-27e2-4c7b-b44a-07a8e56649ed"></a><a name="section-3.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span></h2>
<p class="First">In two multicenter, randomized, double-blind, controlled comparisons of esmolol with placebo and propranolol, maintenance doses of 50 to 300 mcg/kg/min (0.05 to 0.3 mg/kg/min) of esmolol were found to be more effective than placebo and about as effective as propranolol, 3 to 6 mg given by bolus injections, in the treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, principally <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>. The majority of these patients developed their <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> postoperatively. About 60% to 70% of the patients treated with esmolol had a desired therapeutic effect (either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to NSR) and about 95% of those who responded did so at a dosage of 200 mcg/kg/min (0.2 mg/kg/min) or less. The average effective dosage of esmolol was approximately 100 to 115 mcg/kg/min (0.1 to 0.115 mg/kg/min) in the two studies. Other multicenter baseline-controlled studies gave essentially similar results. In the comparison with propranolol, about 50% of patients in both the esmolol and propranolol groups were on concomitant digoxin. Response rates were slightly higher with both beta blockers in the digoxin-treated patients.</p>
<p>In all studies significant decreases of blood pressure occurred in 20% to 50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was symptomatic (mainly <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. In comparison to propranolol, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was about three times as frequent with esmolol, 53% vs. 17%. The <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was rapidly reversible with decreased infusion rate or after discontinuation of therapy with esmolol. For both esmolol and propranolol, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was reported less frequently in patients receiving concomitant digoxin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_edd0e75a-9bcd-40da-82b4-955395425713"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a416cfb1-23a0-4d08-9a37-a8f4646909db"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">Supraventricular Tachycardia</span></h2>
<p class="First">Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol is also indicated in noncompensatory <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span> where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol is not intended for use in chronic settings where transfer to another agent is anticipated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_351b88b2-5ade-4b87-b85c-5b444726083f"></a><a name="section-4.2"></a><p></p>
<h2>Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Esmolol hydrochloride is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.</p>
<p>Use of esmolol to prevent such events is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_4e4116df-10e5-4845-a939-8171b0f169bd"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Esmolol hydrochloride is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> greater than first degree, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> or overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (see <span class="Bold"><a href="#i4i_warnings_id_fbd13e9e-e704-48e7-9019-00f02a9cc8ac"> WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_fbd13e9e-e704-48e7-9019-00f02a9cc8ac"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: </span>In clinical trials 20% to 50% of patients treated with esmolol have experienced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, generally defined as systolic pressure less than 90 mmHg and/or diastolic pressure less than 50 mmHg. About 12% of the patients have been symptomatic (mainly <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>). <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> can occur at any dose but is dose-related so that doses beyond 200 mcg/kg/min (0.2 mg/kg/min) are not recommended. Patients should be closely monitored, especially if pretreatment blood pressure is low. Decrease of dose or termination of infusion reverses <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, usually within 30 minutes.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>: </span>Sympathetic stimulation is necessary in supporting circulatory function in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. Continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, esmolol should be withdrawn. Although withdrawal may be sufficient because of the short elimination half-life of esmolol, specific treatment may also be considered (see <a href="#i4i_overdosage_id_3a1bce57-5d80-4422-8fe0-dc92bc016243">OVERDOSAGE</a>). The use of esmolol for control of ventricular response in patients with supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. Despite the rapid onset and offset of the effects of esmolol, several cases of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in complex clinical states where esmolol was presumably being used to control ventricular rate.</p>
<p><span class="Bold">Intraoperative and Postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: </span>Esmolol should not be used as the treatment for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients in whom the <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> is primarily due to the <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> associated with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>.</p>
<p><span class="Bold">Bronchospastic Diseases: </span>PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS. Because of its relative beta<span class="Sub">1</span> selectivity and titratability, esmolol may be used with caution in patients with bronchospastic diseases. However, since beta<span class="Sub">1</span> selectivity is not absolute, esmolol should be carefully titrated to obtain the lowest possible effective dose. In the event of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, the infusion should be terminated immediately; a beta<span class="Sub">2</span> stimulating agent may be administered if conditions warrant but should be used with particular caution as patients already have rapid ventricular rates.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: </span>Esmolol should be used with caution in diabetic patients requiring a beta blocking agent. Beta blockers may mask <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> occurring with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, but other manifestations such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> may not be significantly affected.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_3a18fbe4-5bdc-4d0c-8536-160287c12df6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_24190278-88b7-409e-b077-a30fb003400c"></a><a name="section-7.1"></a><p></p>
<h2>General </h2>
<p class="First">Infusion concentrations of 20 mg/mL were associated with more serious venous irritation, including <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, than concentrations of 10 mg/mL. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of 20 mg/mL may lead to a serious local reaction and possible <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>. Concentrations greater than 10 mg/mL or infusion into small veins or through a butterfly catheter should be avoided.</p>
<p>Because the acid metabolite of esmolol is primarily excreted unchanged by the kidney, esmolol should be administered with caution to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The elimination half-life of the acid metabolite was prolonged ten-fold and the plasma level was considerably elevated in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
<p>Care should be taken in the intravenous administration of esmolol as <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> of the skin and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> have been reported in association with infiltration and <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of intravenous infusions.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_cfab14ea-f2d1-4d99-abfa-90807f32f02d"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions </h2>
<p class="First">Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents. Patients treated concurrently with esmolol and a catecholamine depletor should therefore be closely observed for evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p>A study of interaction between esmolol and warfarin showed that concomitant administration of esmolol and warfarin does not alter warfarin plasma levels. Esmolol concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.</p>
<p>When digoxin and esmolol were concomitantly administered intravenously to normal volunteers, there was a 10% to 20% increase in digoxin blood levels at some time points. Digoxin did not affect esmolol pharmacokinetics. When intravenous morphine and esmolol were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but esmolol steady-state blood levels were increased by 46% in the presence of morphine. No other pharmacokinetic parameters were changed.</p>
<p>The effect of esmolol on the duration of succinylcholine-induced <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> was studied in patients undergoing surgery. The onset of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> by succinylcholine was unaffected by esmolol, but the duration of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> was prolonged from 5 minutes to 8 minutes.</p>
<p>Although the interactions observed in these studies do not appear to be of major clinical importance, esmolol should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.</p>
<p>While taking beta blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>Caution should be exercised when considering the use of esmolol and verapamil in patients with depressed myocardial function. Fatal <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrests</span> have occurred in patients receiving both drugs. Additionally, esmolol should not be used to control <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> is high.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_91ef89a1-2879-4a78-9f54-c01d65b77ca3"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">Because of its short term usage no carcinogenicity, mutagenicity or reproductive performance studies have been conducted with esmolol.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b6a4bd53-533f-4b67-be1d-10dce689542e"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Category C </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies in rats at intravenous dosages of esmolol up to 3000 mcg/kg/min (3 mg/kg/min) (ten times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, while a dosage of 10,000 mcg/kg/min (10 mg/kg/min) produced maternal toxicity and lethality.  In rabbits, intravenous dosages up to 1000 mcg/kg/min (1 mg/kg/min) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, while 2500 mcg/kg/min (2.5 mg/kg/min) produced minimal maternal toxicity and increased fetal resorptions. </p>
<p>Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span>, which continued after termination of drug infusion. Esmolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_ee0a7920-48e6-4e4e-9a5c-6195fd0715e5"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers </h2>
<p class="First">It is not known whether esmolol is excreted in human milk; however, caution should be exercised when esmolol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_80861b01-fead-47e3-916d-9a2f89a1c80e"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use </h2>
<p class="First">The safety and effectiveness of esmolol in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e864ded7-14d0-4ae6-84da-038cab71b78c"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reaction rates are based on use of esmolol in clinical trials involving 369 patients with <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> and over 600 intraoperative and postoperative patients enrolled in clinical trials. Most adverse effects observed in controlled clinical trial settings have been mild and transient. The most important adverse effect has been <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (see <span class="Bold"><a href="#i4i_warnings_id_fbd13e9e-e704-48e7-9019-00f02a9cc8ac">WARNINGS</a></span>). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have been reported in post-marketing experience occurring during complex clinical states where esmolol was presumably being used simply to control ventricular rate (see <span class="Bold"><a href="#i4i_warnings_id_fbd13e9e-e704-48e7-9019-00f02a9cc8ac">WARNINGS</a>,  <a href="#i4i_overdosage_id_3a1bce57-5d80-4422-8fe0-dc92bc016243"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></span>).</p>
<p><span class="Bold">Cardiovascular </span>– Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) occurred in 12% of patients, and therapy was discontinued in about 11%, about half of whom were symptomatic. Asymptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in about 25% of patients. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> resolved during esmolol infusion in 63% of these patients and within 30 minutes after discontinuation of infusion in 80% of the remaining patients. <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Diaphoresis</span> accompanied <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in 10% of patients. <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">Peripheral ischemia</span> occurred in approximately 1% of patients. <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (heart rate less than 50 beats per minute), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> have each been reported in less than 1% of patients. In two patients without <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> but with serious <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (post <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">inferior myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>), severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>/sinus pause/<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span> has developed, reversible in both cases with discontinuation of treatment. </p>
<p><span class="Bold">Central Nervous System </span>– <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> has occurred in 3% of patients; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> in 3%; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> in about 2%; and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> in about 1% of patients. <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> were reported in less than 1% of patients. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> were also reported in less than 1% of patients, with one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p><span class="Bold">Respiratory </span>– <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">rhonchi</span>, and <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span> have each been reported in less than 1% of patients. </p>
<p><span class="Bold">Gastrointestinal </span>– <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> was reported in 7% of patients. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> has occurred in about 1% of patients. <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> have each occurred in less than 1% of patients. <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span> has also been reported. </p>
<p><span class="Bold">Skin (Infusion Site) </span>– Infusion site reactions including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> were reported in about 8% of patients. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, burning at the infusion site, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, and local <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span> from <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> have each occurred in less than 1% of patients. </p>
<p><span class="Bold">Miscellaneous </span>– Each of the following has been reported in less than 1% of patients: <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, midscapular <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_3a1bce57-5d80-4422-8fe0-dc92bc016243"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1355affd-f9a7-475c-aed2-7470a6827e79"></a><a name="section-9.1"></a><p></p>
<h2>Acute Toxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of esmolol can cause <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. In addition, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> can produce <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4122762" conceptname="Electromechanical dissociation">electromechanical dissociation</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>. Cases of massive accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of esmolol have occurred due to dilution errors. Some of these <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been fatal while others resulted in permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Bolus doses in the range of 625 mg to 2.5 g (12.5 to 50 mg/kg) have been fatal. Patients have recovered completely from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery. The patients who survived appear to be those whose circulation could be supported until the effects of esmolol resolved. </p>
<p>Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the esmolol infusion. Then, based on the observed clinical effects, the following general measures should also be considered. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>: </span>Intravenous administration of atropine or another anticholinergic drug. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: </span>Intravenous administration of beta<span class="Sub">2</span> stimulating agent and/or a theophylline derivative. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>: </span>Intravenous administration of a diuretic and/or digitalis glycoside. In <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> resulting from inadequate cardiac contractility, intravenous administration of dopamine, dobutamine, isoproterenol, or amrinone may be considered. </p>
<p><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: </span>Intravenous administration of fluids and/or pressor agents. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_027fefa5-5606-4f28-a1b2-ff63c351aeae"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Dosing Information: </span></p>
<p><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">SUPRAVENTRICULAR TACHYCARDIA</span></p>
<p>Dosage needs to be titrated, using ventricular rate as the guide. </p>
<p>An initial loading dose of 0.5 milligrams/kg (500 micrograms/kg) infused over a minute duration followed by a maintenance infusion of 0.05 milligrams/kg/min (50 micrograms/kg/min) for the next 4 minutes is recommended. This should give a rough guide with respect to the responsiveness of ventricular rate. </p>
<p>After the 4 minutes of initial maintenance infusion (total treatment duration being 5 minutes), depending upon the desired ventricular response, the maintenance infusion may be continued at 0.05 mg/kg/min or increased step-wise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes. </p>
<p>If more rapid slowing of ventricular response is imperative, the 0.5 mg/kg loading dose infused over a 1 minute period may be repeated, followed by a maintenance infusion of 0.1 mg/kg/min for 4 minutes. Then, depending upon ventricular rate, another (and final) loading dose of 0.5 mg/kg/min infused over a 1 minute period may be administered followed by a maintenance infusion of 0.15 mg/kg/min. If needed, after 4 minutes of the 0.15 mg/kg/min maintenance infusion, the maintenance infusion may be increased to a maximum of 0.2 mg/kg/min.</p>
<p>In the absence of loading doses, constant infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes. Maintenance infusions (with or without loading doses) may be continued for as long as 24 hours. </p>
<p>The following table summarizes the above and assumes that 3 loading doses (the maximum recommended) are infused over a 1 minute and incremental maintenance doses are required after each loading dose.  There should be no 4th loading dose, but the maintenance dose may be incremented one more time. </p>
<table>
<col width="15%">
<col width="14%">
<col width="13%">
<col width="30%">
<col width="28%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>As the desired heart rate or endpoint is approached, the loading infusion may be omitted and the maintenance infusion titrated to 300 mcg/kg/min (0.3 mg/kg/min) or downward as appropriate. Maintenance dosages above 200 mcg/kg/min (0.2 mg/kg/min) have not been shown to have significantly increased benefits. The interval between titration steps may be increased.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Loading Dose</span></p></td>
<td class="Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Maintenance Dose</span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First"><span class="Bold">Elapsed Time</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First">(over 1 minute)</p></td>
<td align="center" colspan="2" valign="top"><p class="First">(over 4 minutes)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">(minutes)</p></td>
<td align="center" valign="top"><p class="First">micrograms/</p></td>
<td align="center" valign="top"><p class="First">milligrams/</p></td>
<td align="center" valign="top"><p class="First">micrograms/</p></td>
<td align="center" valign="top"><p class="First">milligrams/</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">kg/min</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">kg/min</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">kg/min</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">kg/min</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">0 - 1</p></td>
<td align="center" valign="top"><p class="First">500</p></td>
<td align="center" valign="top"><p class="First">0.5</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">1 - 5</p></td>
<td valign="top"></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">50</p></td>
<td align="center" valign="top"><p class="First">0.05</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">5 - 6</p></td>
<td align="center" valign="top"><p class="First">500</p></td>
<td align="center" valign="top"><p class="First">0.5</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">6 - 10</p></td>
<td valign="top"></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">100</p></td>
<td align="center" valign="top"><p class="First">0.1</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">10 - 11</p></td>
<td align="center" valign="top"><p class="First">500</p></td>
<td align="center" valign="top"><p class="First">0.5</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">11 - 15</p></td>
<td valign="top"></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">150</p></td>
<td align="center" valign="top"><p class="First">0.15</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">15 - 16</p></td>
<td align="center" valign="top"><p class="First"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First"><a href="#footnote-1" class="Sup">*</a></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">16 - 20</p></td>
<td valign="top"></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First"><a href="#footnote-1" class="Sup">*</a>200</p></td>
<td align="center" valign="top"><p class="First"><a href="#footnote-1" class="Sup">*</a>0.2</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top"><p class="First">&gt; 20</p></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top"><p class="First">Maintenance dose titrated to heart rate or other clinical endpoint.</p></td>
</tr>
</tbody>
</table>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, responses to esmolol usually (over 95%) occur within the range of 50 to 200 micrograms/kg/min (0.05 to 0.2 milligrams/kg/min).  The average effective dosage is approximately 100 micrograms/kg/min (0.1 milligrams/kg/min) although dosages as low as 25 micrograms/kg/min (0.025 milligrams/kg/min) have been adequate in some patients.  Dosages as high as 300 micrograms/kg/min (0.3 milligrams/kg/min) have been used, but these provide little added effect and increase the rate of adverse effects, so doses greater than 200 micrograms/kg/min are not recommended.  Dosage of esmolol in <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> must be individualized by titration in which each step consists of a loading dosage followed by a maintenance dosage.</p>
<p>This specific dosage regimen has not been studied intraoperatively and, because of the time required for titration, may not be optimal for intraoperative use.</p>
<p>The safety of dosages above 300 mcg/kg/min (0.3 mg/kg/min) has not been studied.</p>
<p>In the event of an adverse reaction, the dosage of esmolol may be reduced or discontinued.  If a local infusion site reaction develops, an alternate infusion site should be used and caution should be taken to prevent <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.  The use of butterfly needles should be avoided.</p>
<p>Abrupt cessation of esmolol in patients has not been reported to produce the withdrawal effects which may occur with abrupt withdrawal of beta blockers following chronic use in <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) patients.  However, caution should still be used in abruptly discontinuing infusions of esmolol in CAD patients.</p>
<p>After achieving an adequate control of the heart rate and a stable clinical status in patients with <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, transition to alternative antiarrhythmic agents such as propranolol, digoxin, or verapamil, may be accomplished.</p>
<p>A recommended guideline for such a transition is given below but the physician should carefully consider the labeling instructions for the alternative agent selected.</p>
<table>
<col width="27%">
<col width="39%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> Alternative Agent </span> </p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> Dosage </span>                                                   </p></td>
</tr>
<tr>
<td valign="top"><p class="First">Propranolol hydrochloride</p></td>
<td valign="top"><p class="First">10 mg to 20 mg q 4 to 6 hrs </p></td>
</tr>
<tr>
<td valign="top"><p class="First">Digoxin </p></td>
<td valign="top"><p class="First">0.125 mg to 0.5 mg q 6 hrs (p.o. or i.v.) </p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Verapamil </p></td>
<td class="Botrule" valign="top"><p class="First">80 mg q 6 hrs </p></td>
</tr>
</tbody>
</table>
<p>The dosage of esmolol should be reduced as follows:</p>
<dl>
<dt>1.</dt>
<dd>Thirty minutes following the first dose of the alternative agent, reduce the infusion rate of esmolol by one-half (50%).</dd>
<dt>2.</dt>
<dd>Following the second dose of the alternative agent, monitor the patient’s response and if satisfactory control is maintained for the first hour, discontinue esmolol.                     </dd>
</dl>
<p>The use of infusions of esmolol up to 24 hours has been well documented; in addition, limited data from 24 to 48 hrs (N=48) indicate that esmolol is well tolerated up to 48 hours.</p>
<p>INTRAOPERATIVE AND POSTOPERATIVE <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">TACHYCARDIA</span> AND/OR <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">HYPERTENSION</span></p>
<p>In the intraoperative and postoperative settings it is not always advisable to slowly titrate the dose of esmolol to a therapeutic effect.  Therefore, two dosing options are presented:  immediate control dosing and a gradual control when the physician has time to titrate.</p>
<dl>
<dt>1.</dt>
<dd>
<span class="Underline">Immediate Control </span><p class="First">For intraoperative treatment of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> give an 80 mg (approximately 1 mg/kg) bolus dose over 30 seconds followed by a 150 mcg/kg/min infusion, if necessary.  Adjust the infusion rate as required up to 300 mcg/kg/min to maintain desired heart rate and/or blood pressure.</p>
</dd>
<dt>2.</dt>
<dd>
<span class="Underline">Gradual Control </span><p class="First">For postoperative <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, the dosing schedule is the same as that used in <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>.  To initiate treatment, administer a loading dosage infusion of 500 mcg/kg/min of esmolol for one minute followed by a four-minute maintenance infusion of 50 mcg/kg/min.  If an adequate therapeutic effect is not observed within five minutes, repeat the same loading dosage and follow with a maintenance infusion increased to 100 mcg/kg/min (see above <a href="#i4i_section_id_f8adcb91-27e2-4c7b-b44a-07a8e56649ed"><span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">SUPRAVENTRICULAR TACHYCARDIA</span></a>)</p>
</dd>
</dl>
<p><span class="Bold"> Notes: </span></p>
<dl>
<dt>1.</dt>
<dd>Higher dosages (250 to 300 mcg/kg/min) may be required for adequate control of blood pressure than those required for the treatment of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, flutter and <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>.  One third of the postoperative hypertensive patients required these higher doses.</dd>
<dt>2.</dt>
<dd>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</dd>
</dl>
<p><span class="Bold">Directions for Use of the 10 mL Ready-to-use Vial (10 milligrams/mL) </span></p>
<p>This dosage form is prediluted to provide a ready-to-use 10 mg/mL concentration recommended for esmolol intravenous administration.  It may be used to administer the appropriate esmolol loading dosage infusions by hand-held syringe while the maintenance infusion is being prepared.</p>
<p>The 10 mL Ready-to-use Vial contains esmolol at a concentration of 10 milligram/mL.  When using a 10 milligrams/mL concentration, a loading dose of 0.5 mg/kg infused over 1 minute period of time, for a 70 kg patient is 3.5 mL.<br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bc3a6590-5333-40a2-8ca3-2b6499520578"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED<br>
</h1>
<p class="First">Esmolol Hydrochloride Injection, 100 mg/10 mL (10 mg/mL)</p>
<p>NDC 67457-182-10<br>carton containing 10, 10 mL Ready-to-use Vials</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Avoid excessive heat.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>REVISED JANUARY 2013<br>MI:ESMOIJ:R2</p>
<p>0643L102</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_671350f4-185a-422e-86c2-62293488c24b"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg/10 mL</h1>
<p class="First"><span class="Bold">NDC 67457-182-10</span></p>
<p><span class="Bold">Esmolol Hydrochloride</span><br><span class="Bold">Injection</span></p>
<p><span class="Bold">100 mg/10 mL</span><br>(10 mg/mL)</p>
<p><span class="Bold">For Intravenous Use</span></p>
<p><span class="Bold">Rx only     10 x 10 mL Single-Dose Vials</span>  </p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>MI:182:10C:R2</p>
<p><span class="Bold">Mylan.com</span></p>
<p>Contains no preservatives.<br>Discard unused portion.</p>
<p><span class="Bold">Each mL contains:</span> 10 mg Esmolol Hydrochloride<br>and Water for Injection. Buffered with 1.688 mg<br>Sodium Acetate Anhydrous (equivalent to 2.8 mg<br>Sodium Acetate Trihydrate) and 0.546 mg Glacial<br>Acetic Acid. Sodium Hydroxide and/or<br>Hydrochloric Acid added for pH adjustment. pH<br>range is 4.5 to 5.5.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying prescribing<br>information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP</span><br><span class="Bold">Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from freezing.</span></p>
<p><span class="Bold">Avoid excessive heat.</span></p>
<p><span class="Bold">Avoid contact with alkalies. Do not use if</span><br><span class="Bold">discolored or if a precipitate is present.</span></p>
<div class="Figure">
<a name="id714"></a><img alt="Esmolol Hydrochloride Injection 100 mg/ 10 mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94f069f9-dd52-4a69-a103-ebdb4294f088&amp;name=aaa7c217-e7e3-4e8e-88ea-6ec5c1a8d1b9-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESMOLOL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">esmolol hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-182</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESMOLOL HYDROCHLORIDE</strong> (ESMOLOL) </td>
<td class="formItem">ESMOLOL HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE ANHYDROUS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-182-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-182-00</td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076474</td>
<td class="formItem">02/21/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aaa7c217-e7e3-4e8e-88ea-6ec5c1a8d1b9</div>
<div>Set id: 94f069f9-dd52-4a69-a103-ebdb4294f088</div>
<div>Version: 4</div>
<div>Effective Time: 20120430</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
